Mode
Text Size
Log in / Sign up
Phase 1 N=34 Randomized Triple-blind Treatment

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

Enrolled (actual)
34
Serious AEs
2.9%
Results posted
Jan 2015
Primary outcome: Primary: Number of Patients With at Least One Adverse Event — 3; 1; 1; 2 Number of patients

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
BIA 9-1067 (Drug); Placebo (Drug)
Age
Adult · 18+ yrs
Sex
Male
Sponsor
Bial - Portela C S.A.
Primary completion
Sep 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With at Least One Adverse Event
3; 1; 1; 2; 1

Summary

The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising dose regimens of BIA 9-1067.

Eligibility Criteria

Inclusion Criteria

  • A signed and dated informed consent form before any study-specific screening procedure is performed.
  • Aged between 18 and 45 years, inclusive.
  • Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and digital 12-lead electrocardiogram (ECG).
  • Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.

Exclusion Criteria

  • Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g. childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunologic, dermatological, haematological, neurologic, or psychiatric disease.
  • Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before study day 1.
  • History of drug abuse within 1 year before study day 1.
  • History of alcoholism within 1 year before day 1. Consumption of more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g
  • Have previously received BIA 9-1067.
  • Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.
  • Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA [3,4-methylenedioxy-methamphetamine; ecstasy]).
  • History of any clinically important drug allergy.
  • Prohibited Treatments: use of any investigational drug within 90 days or prescription drug within 30 days before investigational medical product (IMP) administration.
  • Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) in excess of 6 cups per day (or equivalent), of grapefruit, grapefruit-containing products, or alcoholic beverages within 24 before study day 1.
  • Use of any over-the-counter drugs including herbal supplements (except for the occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended daily allowance) within 7 days before IMP administration.
  • Donation of blood (ie 450 ml) within 90 days before study day 1.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02071810). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search